New combo pills for blood pressure and diabetes pass early safety check

NCT ID NCT07598968

Completed Knowledge-focused Sponsor: Hanlim Pharm. Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two experimental oral drugs, HL1113-R1 and HL1113-R2, in 35 healthy adults to see if they are safe and how the body processes them. The drugs are being developed for high blood pressure and type 2 diabetes. Participants took the drugs alone and together in a crossover design. Since this is a Phase 1 study in healthy people, it does not prove the drugs work for these conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HL1113-R1 and HL1113-R2 (oral drugs for hypertension and type 2 diabetes)
What this could lead to: If successful, this could help develop safer or more effective combination treatments for high blood pressure and type 2 diabetes.
What could go wrong: This is an early Phase 1 trial in healthy people, not patients. It only measures safety and drug levels, not whether the drugs actually work for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE TYPE 2 HYPERTENSION

Contacts and locations

Locations

Central Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.